Opaleye Management Inc. bought a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,345,000 shares of the company’s stock, valued at approximately $24,177,000. Immix Biopharma accounts for about 2.2% of Opaleye Management Inc.’s portfolio, making the stock its 11th biggest position.
A number of other large investors have also recently made changes to their positions in IMMX. Allworth Financial LP bought a new position in Immix Biopharma during the 4th quarter valued at about $30,000. Legal & General Group Plc bought a new stake in Immix Biopharma in the second quarter worth about $41,000. Mathes Company Inc. purchased a new position in shares of Immix Biopharma during the fourth quarter valued at approximately $56,000. Compass Financial Management LLC bought a new position in shares of Immix Biopharma during the second quarter valued at approximately $56,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of Immix Biopharma during the fourth quarter valued at approximately $67,000. 11.26% of the stock is owned by hedge funds and other institutional investors.
Immix Biopharma Trading Up 3.2%
IMMX opened at $12.70 on Friday. Immix Biopharma, Inc. has a 12-month low of $1.94 and a 12-month high of $15.10. The firm has a 50 day moving average of $11.25 and a two-hundred day moving average of $9.95. The firm has a market capitalization of $908.56 million, a PE ratio of -14.43 and a beta of 0.20.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on IMMX shares. HC Wainwright boosted their price objective on Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, August 10th. Lifesci Capital assumed coverage on shares of Immix Biopharma in a report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 price target on the stock. Bank of America began coverage on shares of Immix Biopharma in a research note on Thursday, June 18th. They issued a “buy” rating and a $27.00 target price on the stock. Morgan Stanley decreased their price target on shares of Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Finally, Citigroup reiterated a “market outperform” rating on shares of Immix Biopharma in a report on Friday, August 14th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Immix Biopharma has a consensus rating of “Moderate Buy” and an average target price of $21.29.
Check Out Our Latest Stock Report on Immix Biopharma
Immix Biopharma Company Profile
Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Featured Stories
- Five stocks we like better than Immix Biopharma
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Want to see what other hedge funds are holding IMMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immix Biopharma, Inc. (NASDAQ:IMMX – Free Report).
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
